NCT05096195View on ClinicalTrials.gov

PRevEnting FracturEs in REnal Disease - 1

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Kidney DiseasesDialysis; ComplicationsFragility FractureChronic Kidney Disease-Mineral and Bone Disorder
Interventions
DRUG

Denosumab 60 mg/ml

Details described in intervention arm/group description section.

OTHER

Calcium and vitamin D prophylaxis

Details described in intervention arm/group description section.

DIAGNOSTIC_TEST

Monitoring of post-injection calcium and phosphate

Details described in intervention arm/group description section.

Trial Locations (6)

K7L 2V7

Kingston Health Sciences Centre, Kingston

Unknown

London Health Sciences Centre, London

K1Y 4E9

The Ottawa Hospital, Ottawa

N5A 2Y6

Huron Perth Healthcare Alliance - Stratford General Hospital, Stratford

M5B 1W8

St. Michaels Hospital, Toronto

N4V 0A4

Woodstock Hospital, Woodstock

All Listed Sponsors
collaborator

ICES

INDUSTRY

collaborator

Academic Medical Organization of Southwestern Ontario

OTHER

collaborator

Western University

OTHER

collaborator

The Kidney Foundation of Canada

OTHER

lead

Western University, Canada

OTHER